

AMENDMENT

Please amend the application without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents as follows.

In the Claims

- 1-11. (Cancelled)
12. (Currently amended) A target adipose tissue cell transduced ~~or infected~~ with a lentiviral vector, wherein the lentiviral vector is ~~a retroviral vector, and wherein the retroviral vector is~~ pseudotyped with at least part of an env protein.
13. (Currently amended) A method of transducing ~~or infecting~~ a target adipose tissue cell comprising contacting the cell with a lentiviral vector.
14. (Currently amended) The method of claim 13, wherein the lentiviral vector ~~is a retroviral vector, and wherein the retroviral vector is~~ pseudotyped with at least part of an env protein.
- 15-17. (Cancelled)
18. (Currently amended) The method of claim 13, wherein the lentiviral vector comprises at least one nucleotide sequence of interest (NOI).
19. (Previously presented) The method of claim 18, wherein the at least one NOI is a selection gene, a marker gene, a therapeutic gene, an antisense sequence or a cDNA library.
20. (Previously presented) The method of claim 18, wherein the at least one NOI blocks or inhibits the expression of a gene in the target adipose tissue cell.
21. (Previously presented) The method of claim 18, wherein at least part of the at least one NOI integrates into the genome of the target adipose tissue cell.
22. (Previously presented) The method of claim 18, wherein the at least one NOI encodes a protein of interest (POI).
23. (Original) The method of claim 22, wherein the POI is a therapeutic protein.
24. (Currently amended) A method of delivering an NOI to a target adipose tissue cell, comprising contacting the target adipose tissue cell with ~~a retroviral~~ lentiviral vector, wherein the ~~retroviral~~ lentiviral vector comprises an NOI, and wherein the ~~retroviral~~ lentiviral vector is pseudotyped with at least part of an env protein.
- 25-28. (Cancelled)

29. (Previously presented) The method of claim 14, wherein the at least part of the env protein is a rabies G protein, a VSV-G protein, a cocal virus glycoprotein, or a chandipura virus glycoprotein.

30. (Cancelled)

31. (Currently amended) The method of ~~claim 30~~ claim 13, wherein the lentiviral vector is an HIV-based lentiviral vector or an EIAV-based lentiviral vector.

32. (Previously presented) The method of claim 24, wherein the at least part of the env protein is a rabies G protein, a VSV-G protein, a cocal virus glycoprotein, or a chandipura virus glycoprotein.

33. (Cancelled)

34. (Currently amended) The method of ~~claim 33~~ claim 24, wherein the lentiviral vector is an HIV-based lentiviral vector or an EIAV-based lentiviral vector.

35-37. (Cancelled)

38. (Previously presented) The target adipose tissue cell of claim 12, wherein the at least part of the env protein is a rabies G protein, a VSV-G protein, a cocal virus glycoprotein, or a chandipura virus glycoprotein.

39. (Cancelled)

40. (Currently amended) The target adipose tissue cell of ~~claim 39~~ claim 12, wherein the lentiviral vector is an HIV-based lentiviral vector or an EIAV-based lentiviral vector.